These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22253028)

  • 1. Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease.
    Hesselstrand R; Andréasson K; Wuttge DM; Bozovic G; Scheja A; Saxne T
    Rheumatology (Oxford); 2012 May; 51(5):915-20. PubMed ID: 22253028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker.
    Hesselstrand R; Kassner A; Heinegård D; Saxne T
    Ann Rheum Dis; 2008 Sep; 67(9):1242-8. PubMed ID: 18065498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study.
    Hasegawa M; Asano Y; Endo H; Fujimoto M; Goto D; Ihn H; Inoue K; Ishikawa O; Kawaguchi Y; Kuwana M; Muro Y; Ogawa F; Sasaki T; Takahashi H; Tanaka S; Takehara K; Sato S
    Rheumatology (Oxford); 2012 Jan; 51(1):129-33. PubMed ID: 22072085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis.
    Allanore Y; Borderie D; Lemaréchal H; Cherruau B; Ekindjian OG; Kahan A
    J Rheumatol; 2003 Jan; 30(1):68-73. PubMed ID: 12508392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis.
    Sandqvist G; Hesselstrand R; Eberhardt K
    Scand J Rheumatol; 2009; 38(4):304-10. PubMed ID: 19296402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
    Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
    Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap.
    Gheita TA; Hussein H
    Joint Bone Spine; 2012 Jan; 79(1):51-6. PubMed ID: 21497537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
    Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
    J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.
    Prasse A; Pechkovsky DV; Toews GB; Schäfer M; Eggeling S; Ludwig C; Germann M; Kollert F; Zissel G; Müller-Quernheim J
    Arthritis Rheum; 2007 May; 56(5):1685-93. PubMed ID: 17469163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma.
    Diot E; Diot P; Valat C; Boissinot E; Asquier E; Lemarie E; Guilmot JL
    Eur Respir J; 1995 Sep; 8(9):1559-65. PubMed ID: 8575585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.
    Moore OA; Goh N; Corte T; Rouse H; Hennessy O; Thakkar V; Byron J; Sahhar J; Roddy J; Gabbay E; Youssef P; Nash P; Zochling J; Proudman SM; Stevens W; Nikpour M
    Rheumatology (Oxford); 2013 Jan; 52(1):155-60. PubMed ID: 23065360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years.
    Sharif M; Kirwan JR; Elson CJ; Granell R; Clarke S
    Arthritis Rheum; 2004 Aug; 50(8):2479-88. PubMed ID: 15334461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-brain natriuretic peptide in systemic sclerosis: new insights.
    Elshamy HA; Ibrahim SE; Farouk HM; Moustafa AA; Aly IM; Osman WM
    Eur J Dermatol; 2011; 21(5):686-90. PubMed ID: 21700537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
    Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
    Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
    J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.
    Beretta L; Santaniello A; Lemos A; Masciocchi M; Scorza R
    Rheumatology (Oxford); 2007 Feb; 46(2):296-301. PubMed ID: 16877463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.